ALN-VSP: Additional Phase I data

Additional data from 27 evaluable patients in an open-label, dose-escalation Phase I trial showed that IV ALN-VSP every 2 weeks produced 1 partial response and 7 cases of stable disease. The trial, which enrolled 41 patients, evaluated 7 dose levels of ALN-VSP ranging from 0.1-1.5 mg/kg and identified 1.25 mg/kg every 2 weeks as the recommended Phase II dose. Data are being presented at the American Society of Clinical Oncology meeting in Chicago. ...